• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Rejects Schizophrenia Tx; ADHD & Mental Health; Eating Disorder Treatment Scarce
(MedPage Today) -- The FDA hit Teva Pharmaceuticals and MedinCell with a complete response letter in regard to their new drug application for the schizophrenia treatment TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous...
Source: MedPage Today Psychiatry - April 20, 2022 Category: Psychiatry Source Type: news

Stepped treatment for attention-deficit/hyperactivity disorder and aggressive behavior: a randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization - Blader JC, Pliszka SR, Kafantaris V, Foley CA, Carlson GA, Crowell JA, Bailey BY, Sauder C, Daviss WB, Sinha C, Matthews TL, Margulies DM.
OBJECTIVE: Stimulant medications are the most prevalent first-line pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD), but children with aggressive behavior often receive multi-agent treatment. There is sparse evidence for the benefits of ...
Source: SafetyLit - February 4, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naive youth with attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder and aggression - Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.
BACKGROUND/PURPOSE: Attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) are frequently co-occurring in youth, but data about the pharmacological management of this comorbidity are scarce, especially when impulsive aggres...
Source: SafetyLit - August 25, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-month follow-up of the TOSCA Trial - Gadow KD, Brown NV, Arnold LE, Buchan-Page KA, Bukstein OG, Butter E, Farmer CA, Findling RL, Kolko DJ, Molina BS, Rice RR, Schneider J, Aman MG.
The objective of this study was to evaluate 52-week clinical outcomes of children with co-occurring attention-deficit/hyperactivity disorder (ADHD), disruptive behavior disorder, and serious physical aggression who participated in a prospective,...
Source: SafetyLit - June 15, 2016 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Two drugs reduce teacher-rated anxiety, in addition to ADHD, aggression
The addition of risperidone to parent training and a stimulant also improves teachers’ assessments of anxiety and social avoidance, new research shows. Improvement in teacher-rated anxiety and social withdrawal also contributed to improvements in parent-rated disruptive behavior. Children who showed reduced anxiety also showed less disruptive behavior.
Source: ScienceDaily Headlines - April 17, 2015 Category: Science Source Type: news

Study shows 2 drugs reduce teacher-rated anxiety, in addition to ADHD, aggression
(Ohio State University Wexner Medical Center) A study led by researchers at the Nisonger Center at Ohio State's Wexner Medical Center is available online today in the Journal of Child and Adolescent Psychopharmacology and shows the addition of risperidone to parent training and a stimulant also improves teachers' assessments of anxiety and social avoidance. Improvement in teacher-rated anxiety and social withdrawal also contributed to improvements in parent-rated disruptive behavior. Children who showed reduced anxiety also showed less disruptive behavior.
Source: EurekAlert! - Medicine and Health - April 17, 2015 Category: Global & Universal Source Type: news

Case report: guanfacine overdose
Intuniv (Guanfacine) 3 out of 5 stars Prolonged Bradycardia and Hypotension Following Guanfacine Extended Release Overdose. Walton J et al. J Child Adolesc Physcopharmacol 2014 Jul 10 [Epub ahead of print] Reference  Guanfacine is a central α2-agonist with a mechanism of action similar to that of clonidine. Originally marketed as an antihypertensive agent, it is now available as an extended-release preparation (Imtuniv) for treating children ages 6-17 with attention-deficit hyperactivity disorder (ADHD). It is thought the mechanism of action in that condition may involve stimulation of α2-receptors in the prefrontal c...
Source: The Poison Review - July 18, 2014 Category: Toxicology Authors: Leon Tags: Medical ADHD attention deficit hyperactivity disorder clonidine guanfacine Source Type: news

Myths & Truths about Tourette Syndrome
This study also found a decrease in tics in adults who received CBIT. Unfortunately, behavior therapy isn’t widely available. Medication is used more frequently to treat tics. Doctors typically prescribe clonidine or guanfacine as the first line of treatment, Woods said. They also may prescribe atypical antipsychotics, such as risperidone, he added. 4. Myth: Teaching kids to suppress one tic will trigger more or different tics. Fact: Research has found that when kids successfully suppress their tics, they don’t experience an increase in tics. One study even found that after the suppression condition, tics decreased by...
Source: Psych Central - August 29, 2013 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Atypical Antipsychotics Children and Teens Disorders General Medications Psychotherapy Self-Help Treatment Attention Deficit Hyperactivity Attention Deficit Hyperactivity Disorder Behavior Therapy CBIT Clinical Psychologist Commo Source Type: news